Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Lung, Respiratory and Thoracic Cancer

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Semin Oncol

Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A

doi: 10.1016/j.seminoncol.2025.152431

Lung, Respiratory and Thoracic CancerCOVID-19

Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer

Lung Cancer

Desai RK, Zhou EJ, Chan KKW

doi: 10.1016/j.lungcan.2025.108812

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Wang Y, Zhang L, Zhan J, Wen L, Zhao X, Sun H, Chen X, Zhang Y, Chen G, Zhao Y, Huang Y, Fang W, Zhang L, Sun D, Yang Y

doi: 10.1016/j.lungcan.2026.108914

RECOMMENDED

Head and Neck Cancer

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT

doi: 10.1016/j.lungcan.2025.108858

Lung, Respiratory and Thoracic Cancer

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Lung Cancer

Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S

doi: 10.1016/j.lungcan.2025.108813

Lung, Respiratory and Thoracic Cancer

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

Lung Cancer

Guerrera F, Gallina FT, Balzani E, Ambrosi F, Federico AD, Faccioli E, Facheris G, Ferrara R, Ferro A, Filipello F, Giusti R, Greco C, Mammana M, Marinelli D, Nuccio A, Pittaro A, Sepulcri M, Viscardi G, Bertoglio P

doi: 10.1016/j.lungcan.2025.108760

Breast Cancer

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis

J Natl Cancer Inst

Buonaiuto R, Pagliuca M, Longobardi A, Cataldo ML, Arecco L, Gerosa R, Gentile G, Caltavituro A, Barone I, Karakose B, Agostinetto E, Sotiriou C, De Laurentiis M, De Azambuja E, De Angelis C

doi: 10.1093/jnci/djag220

Lung, Respiratory and Thoracic Cancer

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

J Thorac Oncol

Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ

doi: 10.1016/j.jtho.2026.103651

Related content

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer

Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort